<SEC-DOCUMENT>0001493152-19-000544.txt : 20190114
<SEC-HEADER>0001493152-19-000544.hdr.sgml : 20190114
<ACCEPTANCE-DATETIME>20190114072145
ACCESSION NUMBER:		0001493152-19-000544
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20190114
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190114
DATE AS OF CHANGE:		20190114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		19523631

	BUSINESS ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of earliest event reported): January 14, 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>MICROBOT
MEDICAL INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-19871</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3078125</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
        or other jurisdiction</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
        incorporation)</B></FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Commission</B></FONT></P>
                                                                             <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>File Number)</B></FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(IRS
        Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>25
Recreation Park Drive, Unit 108</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hingham,
Massachusetts 02043</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
of Principal Executive Offices) (Zip Code)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant&rsquo;s
telephone number, including area code: (781) 875-3605</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Former
Name or Former Address, if Changed Since Last Report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
&sect;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-right: 0; margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7.01 Regulation FD Disclosure.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">On
January 14, 2019, Microbot Medical Inc. (the &ldquo;Company&rdquo;) issued a press release announcing that it has validated the
operational effectiveness of the Company&rsquo;s Self-Cleaning Shunt (SCS</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&trade;<FONT STYLE="color: windowtext">)
in a recent independent in-vitro laboratory study. The Company also shared images of its SCS</FONT>&trade; <FONT STYLE="color: windowtext">from
the laboratory study that clearly demonstrate the device prevented shunt occlusion. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">On
January 14, 2019, the Company issued a press release announcing that it </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">received
a notification from the European Patent Office that it will grant a patent for Application No. 08738207, which covers the Company&rsquo;s
ViRob&trade; technology platform. Including this latest notification, the Company has 30 issued/allowed patents and 18 patent
applications pending worldwide. <FONT STYLE="color: windowtext">A copy of the press release is furnished as Exhibit 99.2 to this
Current Report on Form 8-K and is incorporated herein by reference.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this Item 7.01 and in Exhibits 99.1 and 99.2 of Item 9.01 is being furnished pursuant to Item 7.01 and shall not
be deemed to be &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information
in this Item 7.01 or Exhibits 99.1 or 99.2 of Item 9.01.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01 Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.6in; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 0.15in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated January 14, 2019 regarding in-vitro laboratory study</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex99-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated January 14, 2019 regarding ViRob&trade; patent</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: center; text-indent: -63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>MICROBOT MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    <FONT STYLE="font-variant: small-caps">Harel Gadot</FONT></I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Chairman</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    January 14, 2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: Red; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; color: Red; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">Recent
Study Validates the Operational Effectiveness of Microbot Medical&rsquo;s Self-Cleaning Shunt (SCS<SUP>TM</SUP>) </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HINGHAM,
Mass., January 14, 2019</B> &ndash;Microbot Medical Inc. (NASDAQ: MBOT) announced today that it has validated the operational
effectiveness of the Company&rsquo;s Self-Cleaning Shunt (SCS<SUP>TM</SUP>) in a recent independent in-vitro laboratory study.
The Company also shared images of its SCS<SUP>TM</SUP> from the laboratory study that clearly demonstrate the device prevented
shunt occlusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><IMG SRC="ex99-1_002.jpg" ALT="" STYLE="width: 325"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><IMG SRC="ex99-1_003.jpg" ALT="" STYLE="width: 325"></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non
    Activated shunt</FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activated
Shunt</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><IMG SRC="ex99-1_004.jpg" ALT="" STYLE="width: 325">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><IMG SRC="ex99-1_005.jpg" ALT="" STYLE="width: 325">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
    weeks cell growth</FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    minutes post shunt activation</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
believe the highly encouraging results from this latest study, which complements our previous pre-clinical studies, demonstrates
the potential of our SCS<SUP>TM</SUP> product to revolutionize how Hydrocephalus and Normal Pressure Hydrocephalus (NPH) can be
treated in the future,&rdquo; commented Harel Gadot, CEO, President and Chairman. &ldquo;We believe the performance of the SCS<SUP>TM
</SUP>during this and previous studies gives us greater confidence to explore additional medical applications for the device in
conditions where occlusion occurs, such as in the Traumatic Brain Injury (TBI) space.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study was conducted at Envigo CRS Israel, a leading provider of non-clinical contract research services and research models. Human
brain glioblastoma cells were used in order to assess performance of the SCS<SUP>TM</SUP> in a test system with accelerated cell
growth rate, accumulation and obstruction rates. The study commenced in October 2018 and after 30 days it demonstrated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 39.35pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    cell growth and accumulation in a non-operating SCS<SUP>TM</SUP>; and </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    significant inhibition in cell growth in the constantly operating SCS<SUP>TM</SUP> with very little to no cell attachment
    on the robotic brush (ViRob<SUP>TM</SUP>) and on the opening where the robotic brush (ViRob<SUP>TM</SUP>) operates.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study also demonstrated that the Company&rsquo;s SCS<SUP>TM</SUP> has the ability to operate after cells had accumulated on the
catheter holes and the robotic brush (ViRob<SUP>TM</SUP>). Moreover, SCS<SUP>TM</SUP> activation demonstrated the potential to
disintegrate existing occlusions formed on the robotic brush (ViRob<SUP>TM</SUP>) and on the opening where the robotic brush (ViRob<SUP>TM</SUP>)
operates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to this study, the Company previously announced data from two pre-clinical studies that were performed at leading U.S.
academic institutions. Data from those studies were also presented by Professor Pat McAllister, Department of Neurosurgery, Washington
University School of Medicine, St. Louis, at the International Hydrocephalus Conference, held in Bologna, Italy in October 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In-vitro
    study, which was performed at Wayne State University, supports the SCS<SUP>TM</SUP>&rsquo;s potential as a viable technology
    for preventing occlusion in shunts used to treat hydrocephalus.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In-vivo
    animal study, which was performed at Washington University School of Medicine in St. Louis, supports the safety profile of
    the Company&rsquo;s SCS<SUP>TM</SUP> as a CSF catheter.&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
follow up study, which is being conducted by the same academic institutions, commenced in October 2018 and includes a larger sample
size compared to the initial studies. The primary and secondary endpoints will seek to validate the safety and efficacy of the
SCS<SUP>TM</SUP> that will be activated in both in-vitro (lab) and in-vivo (animal) models. The Company&rsquo;s objective is to
conclude the follow up study and announce the data in the second half of 2019. The Company plans to use the findings either for
its regulatory submissions in the US, Europe and other jurisdictions, or as part of a pre-submission meeting request, depending
on the final results of the ongoing follow-up study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Envigo</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
over 3,300+ employees serving over 65 countries with a network of more than 25 operating facilities worldwide, Envigo provides
comprehensive scientific expertise and a full service offering in non-clinical research and development, research models and services,
regulatory consulting, and analytical support to our customers. Envigo is a privately held global company with corporate headquarters
in New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Microbot Medical, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&trade;,
which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes
in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot&rsquo;s
current technological platforms, ViRob<SUP>TM</SUP>, TipCAT<SUP>TM</SUP> and CardioSert<SUP>TM</SUP>, are comprised of three highly
advanced technologies, from which the Company is currently developing its first product candidate: The Self-Cleaning Shunt, or
SCS<SUP>TM</SUP>, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH. The Company also is focused on
the development of a Multi Generation Pipeline Portfolio (MGPP) utilizing all technologies. Further information about Microbot
Medical is available at http://www.microbotmedical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ViRob<SUP>TM</SUP> technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the
body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels,
the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages
as well as the ability to remain within the human body for prolonged time. To learn more about ViRob<SUP>TM</SUP> please visit
http://www.microbotmedical.com/technology/virob/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TipCAT<SUP>TM
</SUP>is a transformational self-propelled, flexible, and semi-disposable locomotive device providing see &amp; treat capabilities
within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly
suitable to navigate and crawl through natural &amp; artificial tubular lumens, applying the minimal necessary pressure to achieve
the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT<SUP>TM</SUP>,
visit http://www.microbotmedical.com/technology/tipcat/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CardioSert<SUP>TM
</SUP>technology contemplates a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal
surgery. The CardioSert<SUP>TM</SUP> technology features unique steering and stiffness control capabilities, and it was originally
developed to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during
percutaneous coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as
peripheral intervention, neurosurgery and urology. CardioSert<SUP>TM</SUP> was part of a technological incubator supported by
the Israel Innovation Authorities (formerly known as the Office of the Chief Scientist, or OCS), and its device has successfully
completed pre-clinical testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;expects&rdquo; and &ldquo;estimates&rdquo;) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development
and/or commercialization of potential products, the outcome of its studies to evaluate the SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, need and ability
to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results
anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect
the businesses of Microbot Medical Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.&rsquo;s
filings with the Securities and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Polyviou</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVC
Group</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mpolyviou@evcgroup.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">732-933-2754</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !D /X# 2(  A$! Q$!_\0
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M,UEC\/2E.&+J5W)XC+:JE)?5LW3A"67U4_=P\,73@ZU%4JE*52G.%27PN?\
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MHM_LA),PP5".IW;=DOS/@@'&Y%B!&?XIE&.C&N*U[XF>!?"[^7XB\7>'=$D
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M$-_HJ/),[[LAV<H1M!VDE@OLUO+YR"10VQ@"N[(;.2&!4],<<YYST&*_D_\
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MKOD0(0J('DO)HPPVG>(1+L0'T+#;N*U_:1\(Y##\"_!09#YW_"OM/=HAV/\
M82N%#]#D6^,X&"XXXY_BX^(\T1\:^* L]J%77O$%LQEN8X60V\EW"S,AW$;M
MFX+GN5R=N2*2N]>NFC _HQ_X)&,Q_8:9&9GQ<^+Y<L<C,MM?Y"K_  @; , X
M.!P,5_.7\2"1XO\ %+#G&H:]\OK_ *9J/?DC'T-?T8_\$ARLG[#[*S*NZZ\4
MQ H1(&WQWD2/'C;O!\TL0,;=H'.[*_SC_$67?XM\32YBV_;M;)Q-&50R2W<S
M+*V04*>:$ VG?@M\O J)--MK^M /UQ^%/C#5/"G_  2'NM0TMGM1<Z]8:9>7
M4;,'M[>[\:Z )2SJ%V1R6L=W%(20%5]QX7:WXG>(6.MQI%>27D!U;Q18:=JT
MD3XN0+O68[6XTW.%-Q8VEO<FYEO2T2S+.(O(BQYK?T@?\$_/A!H_QX_X)KZI
M\+-9"F#Q98^(["WRRD6^H2?:&TN[3YXP[6]XD-PN)(B#"%\Q0Y=/P&^+GPV\
M4?!CQWKOPP^)5A=Z%K^D2WUC'>W<!BMM0TOS)?)U+3;AV"/>E6LFDC5Y'5H8
M?WQ\[*7&222;_/N!_8]^RW\*O!?P@^"7@+P[X&T>QTNRC\.:?/=QZ9'##%?3
MWL8>:[G56R991&)(Y3-+M9G^4@DM[E>>'-(U&Z@U&XTRQN=3L8LV.I7=G;3Z
ME#(/F1(KYM\F  X  7:.1NYK^;K]EC_@J+XU^%?A#2/ _P 1K/2?%FAZ/;K;
M:'?S37$6IQZ19VEM;V]M=""QO"\Q,9FWR7"X\QD"MM9S]$^&/^"IVJ_$W]H_
MX$?#SP58V=GX9\8>+;S3O%"&V=&BMI+*/[&#(T8>81N;L$@0'+*S$<8.9=]>
MF_W;?U<#YJ_X+$R"3]HC1U61F5/!FG/@J "I*<*PP2&=7SD'&.AS7S?_ ,$Q
M?AEX:^)G[:V@_P#"6V5OJUGX*\):QXATK3[NW2XM?MTC6F&D1V*YC:UB9'V-
MCGY><U]$?\%A9E'[0GATR&))9?AYIF8DGC+R3?;KL#RED,.2RE"RCF,; =VX
M$<!_P2$$D?[9FLRRV\Z"#X8ZG)(H$<C(GF1J6(CD8<;P>2.G&3T?-'O^#_R
M_J;U*TCMM)N#!;02/;V,\MO;&(?9U=;>6=([> ';"Y:VC2.52QC.'"'!4_Q/
M_'OQ-J'BOXJ^,K_5Y[IKC3_$&JZ<;*3HUS)JU[+<V<K$%IH2@M%G!1?-\N(@
MIC%?VZ7+[U:(*63RE60J"2$<+LDSQMWJ9T*C=C&20, _R<?\%)OV6O$_P(^,
M_BCXF6.D:A=_#'Q]JUQJT&LV<$EQ::!K=XUF5MKZ*,RB*&9Y)2+MGB!\N0F
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M; O%\W)@IRE[64L&J+YXMU6YR]JOXCO'2S/Y]?"-GJ>J^,_!W@[3+V#3M/\
M&.MC1[W^TLR:9;-=2P118CE\U(UN7W>?-MV1!$VQ &OZ*/A7\?/B+^Q_+I'P
MD_:+^'L6D^!;*.RL/#?Q2\(:7%>>$'LKL$61U74;.V@6 !73[1=2028+892
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M:@OG+GRD#%BJ??X!.2=^LW2HO*M(AV\J!%S'Y95+>".V"GYFSEH6E X""4*
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MB\\WB6P\':/;V]Q;GS[GR/\ A)_B&TEZSQ9='6)E7RBCE-A/F_-@?NU\&?\
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M_+GZ[<$T44 11*NQ\#'*]R<X/&=Q/J?S^E6"BLV2 2 .OU/;\*** $(",NT
M!LY'T(Q]/O']*7RT_NBBB@!A196.\9V?=ZC&[(/3UVC_ /54@15Z*/Y_SS11
,0 [ '0 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #" 5<# 2(  A$! Q$!_\0
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M#_XT'7]8'_,6OO\ P)?_ !KGFG<G%-,\O3- SHO^$@UC_H*WW_@2_P#C2?\
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M@B\+V$44B&/?NS@MV]*HW/@R$HQ@F:-F'S =#W _,"A.5[,1Q(LD* !3N &
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MTM.Y+.X^ W_(>\:?[]I_*6BCX#?\AWQG_OVG\I:*10SQU!&_CC5'923NC_\
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MX())]A3.!U-+CT--QB@!C4H(SBE:F_=((Q^(H 4KWIA^4@GI4BL#P3S3M@-
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M([4TH?2K13FDVB@+E3:1[TF.:M[13=BXZ4QW*^,TW)[U.5' [TFW!Z4@.M^
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MT[8,Y[UJ#P_K'_0)OO\ P'?_  I?[ UC_H$WW_@._P#A3 RM@H K5_L#6?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_003.jpg
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #" 5<# 2(  A$! Q$!_\0
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M (6%XC_Z"7_D"/\ ^)H_X6'XC_Z"/_D"/_XFN4(],T8;TH ZD_$3Q)_T$?\
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M/_A1_8&L_P#0(O\ _P !G_PH$9U)6E_8&L_] B__ / 9_P#"C^P-9_Z!%_\
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M?5_\*:/#6O8_Y FI?^ C_P"%(9EXI"*V/^$:UW_H"ZC_ . K_P"%-/AK7?\
MH":E_P" K_X4 =_\$O\ D6];_P"PQ)_Z)AHJS\(--OM,T#6(K^RN+22357D1
M9XFC++Y40W $<C((S[&BI&>AT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_004.jpg
<TEXT>
begin 644 ex99-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #% 5X# 2(  A$! Q$!_\0
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M= '1_P#"P?$__03_ /)>+_XF@?$#Q1_T$_\ R7B_^)KFMIH H$=./'_B<_\
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M\6C\5:A&<&X?KGK5]/&>H\8NG^AQ6:E46\2KGK5)PW P<=:\Q3QYJ"CEU/U
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M#B .)^?I1[3R869Y7'; R /PO<XZ4NR/R3P0Z]".]>ER>!U%E*@(,I8#?V4
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M"QKMRD?AK4$E7=)+"=A#?=^M?4M?(&K[_P"R+K(X\LU]?TF-&>?^0]_VZ_\
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MU$*>*!$ZU(.M0K4JT@)5.!3]U1"G'I2 "V*;NCR-Q(%-8U"_2FM .A&E:3)
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J//\ S!__ "9F_P#BZ** &2_"OP7/$T4FC;D88(^U3#/_ (_78T44 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-1_005.jpg
<TEXT>
begin 644 ex99-1_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #$ 5T# 2(  A$! Q$!_\0
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M7!J,#FJ L1MTJ;.*KQBK'&VI8$;MFH6-3-5=FR:2 4$^M D8+P:;GVIW&.:
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M.W%;%5&,6KB: <4445?*AA5"_60+D?<]JOTC*&&",BLJE/F6@&'';S3,2KL
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M:0A:C;I3R>*C:BP$35$14K5&>M,8@%+B@4HI  %+B@4X4 -VTH6EI: &X%
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M+24 1D5$PR:F:HR,G- &=JJ#^RKDX&=AKZF\"?\ )/?#7_8*M?\ T4M?+NK
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MF_\ @)'_ (444 '_  C&@?\ 0#TS_P !(_\ "C_A&/#_ /T M,_\!(_\***
M#_A&/#__ $ M,_\  2/_  H_X1CP_P#] +3/_ 2/_"BB@ _X1CP__P! /3/_
M  $C_P */^$8\/\ _0"TS_P$C_PHHH /^$8\/_\ 0"TS_P !(_\ "C_A&/#_
M /T M,_\!(_\*** #_A&/#__ $ M,_\  2/_  H_X1CP_P#] /3/_ 2/_"BB
M@ _X1CP__P! +3/_  $C_P */^$8\/\ _0"TS_P$C_PHHH /^$8\/_\ 0"TS
M_P !(_\ "C_A%_#_ /T M,_\!(_\*** #_A&/#__ $ M,_\  2/_  H_X1CP
M_P#] +3/_ 2/_"BB@ _X1?P__P! +3/_  $C_P */^$7\/\ _0"TS_P$C_PH
MHH 3_A%_#_\ T M,_P# 2/\ PH_X1?P__P! +3/_  $C_P *** #_A%_#W_0
M"TS_ ,!(_P#"C_A%O#W_ $ =+_\  ./_  HHH /^$6\/?] '2_\ P#C_ ,*3
M_A%?#O\ T =+_P# ./\ PHHH 7_A%O#W_0!TO_P#C_PI/^$5\._] '2__ ./
M_"BB@!'\)>&Y$*/X>TEE/!5K*,@_I6I!!#:V\5O;Q1PP1($CCC4*J*!@  <
( <8HHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>8
<FILENAME>ex99-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center"><IMG SRC="ex99-2_001.jpg" ALT=""></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">Microbot
Medical Increases its Global IP Portfolio with Notice of Allowance from the European Patent Office</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HINGHAM,
Mass., January 14, 2019</B> &ndash; Microbot Medical Inc. (NASDAQ: MBOT), received a notification from the European Patent Office
that it will grant a patent for Application No. 08738207, which covers the Company&rsquo;s ViRob&trade; technology platform. Including
this latest notification, the Company has 30 issued/allowed patents and 18 patent applications pending worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
allowance of this European patent application further strengthens our global intellectual property estate covering micro-robotic
technology platform,&rdquo; commented Harel Gadot, CEO, President and Chairman. &ldquo;As we have demonstrated since becoming
a publicly traded company, we are creating significant barriers to entry and this combined with the positive safety data we continue
to achieve with our Self-Cleaning Shunt (SCS&trade;), are reinforcing our pillars for success.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
allowed application covers an autonomous vibration-driven device for motion relative to a juxtaposed surface, such as an inner
wall of a lumen. The device includes a body and an array of fibers attached thereto, with at least some of the fibers maintaining
contact with the juxtaposed surface and having anisotropic surface friction therewith, such that mutual vibratory motion between
the device and the juxtaposed surface causes the device to move along the surface.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Microbot Medical, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&trade;,
which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes
in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot&rsquo;s
current technological platforms, ViRob<SUP>TM</SUP>, TipCAT<SUP>TM</SUP> and CardioSert<SUP>TM</SUP>, are comprised of three highly
advanced technologies, from which the Company is currently developing its first product candidate: the Self Cleaning Shunt, or
SCS<SUP>TM</SUP>, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and focusing on the development
of a Multi Generation Pipeline Portfolio (MGPP) utilizing all technologies. Further information about Microbot Medical is available
at http://www.microbotmedical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ViRob<SUP>TM</SUP> technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the
body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels,
the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages
as well as the ability to remain within the human body for prolonged time. To learn more about ViRob<SUP>TM</SUP> please visit
http://www.microbotmedical.com/technology/virob/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TipCAT<SUP>TM
</SUP>is a transformational self-propelled, flexible, and semi-disposable endoscope providing see &amp; treat capabilities within
tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly
suitable to navigate and crawl through natural &amp; artificial tubular lumens, applying the minimal necessary pressure to achieve
the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT<SUP>TM</SUP>,
visit http://www.microbotmedical.com/technology/tipcat/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CardioSert<SUP>TM
</SUP>technology is a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal
surgery. The CardioSert<SUP>TM</SUP> technology features unique steering and stiffness control capabilities, and it was originally
developed to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during
percutaneous coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as
peripheral intervention, neurosurgery and urology. CardioSert<SUP>TM</SUP> was part of a technological incubator supported by
the Israel Innovation Authorities (formerly known as the Office of the Chief Scientist, or OCS), and its device has successfully
completed pre-clinical testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;expects&rdquo; and &ldquo;estimates&rdquo;) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development
and/or commercialization of potential products, the outcome of its studies to evaluate the SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many uncertainties that affect the businesses of Microbot Medical
Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.&rsquo;s filings with the Securities
and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contacts: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Polyviou</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVC
Group</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mpolyviou@evcgroup.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">732-933-2754</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex99-2_001.jpg
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !@ 0(# 2(  A$! Q$!_\0
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MYUY3;6FO:\/,M;1S"OR@L=H./2JEU:7NG3>5>V[0OUP>0?QKJLMSG5SW56R
M0<@\TI/&:\R\'>)Y[6]CTZ[E:2"7B-F_@/I6QXL\3FT+6MN3NZ''^?\ .:+
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M#VJSXY\-SRS?VI9QF0XQ,B]<>HKB=/U&73KL7%O,8I!PV>#]"#3 ]S;8RD.
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M[O2?^01:?]<5_D* +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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%** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
